 Clene Inc NASDAQ: CLNN reported significantly improved survival in Amyotrophic lateral sclerosis ALS patients initially treated with CNM-Au8 compared to initially randomized placebo-treated participants during the long-term open-label extension of its RESCUE-ALS trial. Rob. 